company background image
MGCL.F

MGC Pharmaceuticals OTCPK:MGCL.F Stock Report

Last Price

US$0.007

Market Cap

US$24.7m

7D

-30.0%

1Y

-76.0%

Updated

02 Dec, 2022

Data

Company Financials +
MGCL.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

MGCL.F Stock Overview

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide.

MGC Pharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MGC Pharmaceuticals
Historical stock prices
Current Share PriceAU$0.007
52 Week HighAU$0.039
52 Week LowAU$0.0069
Beta1.58
1 Month Change-36.36%
3 Month Change-47.76%
1 Year Change-76.03%
3 Year Change-75.27%
5 Year Change-90.14%
Change since IPO-82.50%

Recent News & Updates

Recent updates

Shareholder Returns

MGCL.FUS PharmaceuticalsUS Market
7D-30.0%2.4%1.5%
1Y-76.0%15.5%-14.9%

Return vs Industry: MGCL.F underperformed the US Pharmaceuticals industry which returned 15.5% over the past year.

Return vs Market: MGCL.F underperformed the US Market which returned -16.1% over the past year.

Price Volatility

Is MGCL.F's price volatile compared to industry and market?
MGCL.F volatility
MGCL.F Average Weekly Movement40.4%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: MGCL.F is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 40% a week.

Volatility Over Time: MGCL.F's weekly volatility has increased from 34% to 40% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014n/aRoby Zomerhttps://mgcpharma.com.au

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia.

MGC Pharmaceuticals Limited Fundamentals Summary

How do MGC Pharmaceuticals's earnings and revenue compare to its market cap?
MGCL.F fundamental statistics
Market CapUS$24.72m
Earnings (TTM)-US$13.80m
Revenue (TTM)US$3.21m

7.7x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MGCL.F income statement (TTM)
RevenueAU$4.73m
Cost of RevenueAU$4.17m
Gross ProfitAU$562.87k
Other ExpensesAU$20.91m
Earnings-AU$20.35m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.007
Gross Margin11.89%
Net Profit Margin-430.00%
Debt/Equity Ratio40.5%

How did MGCL.F perform over the long term?

See historical performance and comparison